Scientists map route for eliciting HIV-neutralizing antibodies
Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according to a study appearing in Science Express this week. The discoveries were made by a team led by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
"This elegant research brings us another step closer to an HIV vaccine and establishes a potent new technique for evaluating the human immune response to experimental vaccines, not only for HIV, but for pathogens generally," said NIAID Director Anthony S. Fauci, M.D.
The new findings build on last year's discovery reported by VRC scientists of three HIV antibodies, two of which could stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory. Called VRC01, VRC02 and VRC03, these antibodies were found in blood donated for NIAID studies by an HIV-infected North American known as donor 45. In the new paper, scientists report discovering antibodies similar to VRC01 in the blood of two HIV-infected Africans known as donor 74 and donor 0219.
The researchers further discovered that these VRC01-like antibodies all bind to the same spot on HIV in the same way. This suggests that an HIV vaccine should contain a protein replica of this spot, known as the CD4 binding site, to elicit antibodies as powerful as VRC01, according to the researchers. The CD4 binding site is one of the few parts of the continuously mutating virus that stays the same across HIV variants worldwide, and the virus uses this site to attach to the cells it infects.
The scientists previously found that the genes for VRC01-like antibodies undergo an unusually high number of mutations70 to 90between the first draft that codes for a weak antibody and the final version that codes for an antibody that can neutralize HIV. These genes lie in the DNA of immune cells called B cells.
"To make a vaccine that elicits VRC01-like antibodies, we will need to coach B cells to evolve their antibody genes along one of several pathways, which we have now identified, from infancy to a mature, HIV-fighting form," said VRC Director Gary J. Nabel, M.D., Ph.D.
To guide B cells along this extended evolutionary pathway, the scientists first needed to map the route. They began by turning to an existing technology to sequence the collection of B-cell genes that code for all the antibodies created by a person's immune system. This study marks the first time this technology, called deep sequencing, has been used to track the evolution of the antibody response to HIV at the genetic level. The NIH researchers then devised sophisticated bioinformatics techniques to decipher the large library of genetic data produced by deep sequencing.
"We found a way to read the books, or genes, in this library by defining unique characteristics of VRC01-like antibodies," said Peter Kwong, Ph.D., chief of the VRC's structural biology section and co-principal investigator of the study.
Based on their discovery of the common structure and genetic origin of the VRC01-like antibodies, the scientists devised strategies for scanning the B-cell DNA libraries of donor 45 and donor 74. From hundreds of thousands of antibody genes, the scientists first identified thousands that code for VRC01-like antibodies and then sorted these genes into family trees showing their evolution from their earliest stage into mature forms. The genes that coded for HIV neutralizing antibodies grouped together on the same branches of the trees.
Next, the researchers focused on the gene segment that codes for the part of the VRC01-like antibody that attaches to and neutralizes HIV. Examining this sequence in the genes of the newfound relatives of VRC01 revealed how the sequence changed step by step along one of a few clear paths from its original state into a mature form. A vaccine that elicits VRC01-like antibodies would need to coax the B-cell DNA of immature antibodies to evolve along one of these pathways.
The scientists now aim to create proteins they can deliver through a vaccine to serve as signposts that direct the development of B-cell DNA to produce VRC01-like antibodies.
The new research has far-reaching implications for vaccine development. "As we develop and test new HIV vaccines, it will be possible to analyze not just antibodies in the blood, but also the specific B-cell genes that are responsible for producing antibodies against HIV," said John R. Mascola, M.D., deputy director of the VRC and co-principal investigator of the study. "This information will indicate whether an investigational HIV vaccine in a preclinical or clinical trial is heading in the right direction."
More information: X Wu et al. Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing. Science Express (online on Aug. 11, 2011).
Provided by National Institutes of Health
- Scientists find antibodies that prevent most HIV strains from infecting human cells Jul 08, 2010 | not rated yet | 0
- Neutralizing HIV Jul 18, 2011 | not rated yet | 0
- New strategy proposed for designing antibody-based HIV vaccine Jun 14, 2009 | not rated yet | 0
- New technology opens gateway to studying HIV-specific neutralizing antibodies Mar 16, 2009 | not rated yet | 0
- Exhausted B cells fail to fight HIV Jul 14, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011 I'd like to open a discussion thread for version 2 of the draft of my book ''Classical and Quantum Mechanics via Lie algebras'', available online at http://lanl.arxiv.org/abs/0810.1019 , and for the...
- More from Physics Forums - Independent Research
More news stories
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
HIV & AIDS 17 hours ago | not rated yet | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
HIV & AIDS May 18, 2013 | 5 / 5 (2) | 0
Researchers at the University of Cincinnati (UC) have found that incorporating a peer-referral program for HIV testing into emergency departments can reach new groups of high-risk patients and brings more patients into the ...
HIV & AIDS May 17, 2013 | not rated yet | 0
(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.
HIV & AIDS May 17, 2013 | not rated yet | 0
A new Yale study looks at the scope and consequences of a burgeoning health problem in the cities of the U.S. Northeast: concurrent infection with both HIV and Hepatitis C (HCV). The study appears online ...
HIV & AIDS May 17, 2013 | not rated yet | 0
A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. Findings from the Framingham Foot ...
20 minutes ago | not rated yet | 0 |
Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.
7 minutes ago | not rated yet | 0 |
Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications.
29 minutes ago | not rated yet | 0
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic ...
13 minutes ago | not rated yet | 0
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
13 hours ago | 4.8 / 5 (5) | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
13 hours ago | 5 / 5 (3) | 0 |